External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients

被引:6
作者
van Kleef, J. J. [1 ]
van den Boorn, H. G. [1 ]
Verhoeven, R. H. A. [2 ]
Vanschoenbeek, K. [3 ]
Abu-Hanna, A. [4 ]
Zwinderman, A. H. [5 ]
Sprangers, M. A. G. [6 ]
van Oijen, M. G. H. [1 ]
De Schutter, H. [3 ]
van Laarhoven, H. W. M. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, NL-3511 DT Utrecht, Netherlands
[3] Belgian Canc Registry, B-1210 Brussels, Belgium
[4] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, NL-1105 AZ Amsterdam, Netherlands
[6] Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Acad Med Ctr, Dept Med Psychol,Amsterdam Univ Med Ctr, NL-1105 AZ Amsterdam, Netherlands
关键词
prediction model; external validation; oesophageal cancer; gastric cancer; CLINICAL-PRACTICE GUIDELINES; DIAGNOSIS; CHEMOTHERAPY; RISK;
D O I
10.3390/cancers12040834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The SOURCE prediction model predicts individualised survival conditional on various treatments for patients with metastatic oesophageal or gastric cancer. The aim of this study was to validate SOURCE in an external cohort from the Belgian Cancer Registry. Data of Belgian patients diagnosed with metastatic disease between 2004 and 2014 were extracted (n = 4097). Model calibration and discrimination (c-indices) were determined. A total of 2514 patients with oesophageal cancer and 1583 patients with gastric cancer with a median survival of 7.7 and 5.4 months, respectively, were included. The oesophageal cancer model showed poor calibration (intercept: 0.30, slope: 0.42) with an absolute mean prediction error of 14.6%. The mean difference between predicted and observed survival was -2.6%. The concordance index (c-index) of the oesophageal model was 0.64. The gastric cancer model showed good calibration (intercept: 0.02, slope: 0.91) with an absolute mean prediction error of 2.5%. The mean difference between predicted and observed survival was 2.0%. The c-index of the gastric cancer model was 0.66. The SOURCE gastric cancer model was well calibrated and had a similar performance in the Belgian cohort compared with the Dutch internal validation. However, the oesophageal cancer model had not. Our findings underscore the importance of evaluating the performance of prediction models in other populations.
引用
收藏
页数:15
相关论文
共 25 条
  • [1] What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study
    Audrey, Suzanne
    Abel, Julian
    Blazeby, Jane M.
    Falk, Stephen
    Campbell, Rona
    [J]. BRITISH MEDICAL JOURNAL, 2008, 337 (7668): : 492 - 496
  • [2] Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study
    Babaei, Masoud
    Balavarca, Yesilda
    Jansen, Lina
    Lemmens, Valery
    van Erning, Felice N.
    van Eycken, Liesbet
    Vaes, Evelien
    Sjovall, Annika
    Glimelius, Bengt
    Ulrich, Cornelia M.
    Schrotz-King, Petra
    Brenner, Hermann
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (07) : 1480 - 1489
  • [3] Belgian Cancer Registry, 2015, CANC BURD BELG
  • [4] Does Use of the Adjuvant! Model Influence Use of Adjuvant Therapy Through Better Risk Communication?
    Belkora, Jeffrey K.
    Hutton, David W.
    Moore, Dan H.
    Siminoff, Laura A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (07): : 707 - 712
  • [5] International comparison of treatment strategy and survival in metastatic gastric cancer
    Claassen, Y. H. M.
    Bastiaannet, E.
    Hartgrink, H. H.
    Dikken, J. L.
    de Steur, W. O.
    Slingerland, M.
    Verhoeven, R. H. A.
    van Eycken, E.
    de Schutter, H.
    Lindblad, M.
    Hedberg, J.
    Johnson, E.
    Hjortland, G. O.
    Jensen, L. S.
    Larsson, H. J.
    Koessler, T.
    Chevallay, M.
    Allum, W. H.
    van de Velde, C. J. H.
    [J]. BJS OPEN, 2019, 3 (01): : 56 - 61
  • [6] Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement
    Collins, Gary S.
    Reitsma, Johannes B.
    Altman, Douglas G.
    Moons, Karel G. M.
    [J]. EUROPEAN UROLOGY, 2015, 67 (06) : 1142 - 1151
  • [7] External validation of multivariable prediction models: a systematic review of methodological conduct and reporting
    Collins, Gary S.
    de Groot, Joris A.
    Dutton, Susan
    Omar, Omar
    Shanyinde, Milensu
    Tajar, Abdelouahid
    Voysey, Merryn
    Wharton, Rose
    Yu, Ly-Mee
    Moons, Karel G.
    Altman, Douglas G.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
  • [8] Predicting and Communicating the Risk of Recurrence and Death in Women With Early-Stage Breast Cancer: A Systematic Review of Risk Prediction Models
    Engelhardt, Ellen G.
    Garvelink, Mirjam M.
    de Haes, J. C. J. M.
    van der Hoeven, Jacobus J. M.
    Smets, Ellen M. A.
    Pieterse, Arwen H.
    Stiggelbout, Anne M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03) : 238 - +
  • [9] When the treatment goal is not cure: Are cancer patients equipped to make informed decisions?
    Gattellari, M
    Voigt, KJ
    Butow, PN
    Tattersall, MHN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 503 - 513
  • [10] A systematic review of physicians' survival predictions in terminally ill cancer patients
    Glare, P
    Virik, K
    Jones, M
    Hudson, M
    Eychmuller, S
    Simes, J
    Christakis, N
    [J]. BRITISH MEDICAL JOURNAL, 2003, 327 (7408): : 195 - 198